The Cepham Inc. research and development (R&D) team will present "Safety, Efficacy and Toxicological Evaluation of a Novel, Patented Anti-Diabetic Extract of Trigonella foenum-graceum Seed Extract (CR001810)" at the 53rd Annual Meeting of the Society of Toxicology on March 24 in Phoenix.

March 21, 2014

1 Min Read
Cepham to Present Abstract at Society of Toxicology Meeting

The Cepham Inc. research and development (R&D) team will present "Safety, Efficacy and Toxicological Evaluation of a Novel, Patented Anti-Diabetic Extract of Trigonella foenum-graceum Seed Extract (CR001810)" at the 53rd Annual Meeting of the Society of Toxicology on March 24 in Phoenix. The presentation marks the introduction of the abstract of a soon-to-be published study on the safety and efficacy of Fenfuro, a novel patented furostanolic saponins-enriched fenugreek (Trigonella foenum-graceum) extract from Cepham.

The unpublished study found that Fenfuro demonstrated a broad safety spectrum. The acute oral toxicology is greater than 5,000 mg/kg body weight in rats and mice.  Fenfuro (150 mg/kg po) also  reduced the plasma triglyceride level in type 2 diabetic rats by 22 percetn, 24.6 percent and 29 percent at 10-, 20- and 30 days of treatment, respectively. Fenfuro also exhibited significant hypoglycemic activty in the diabetic rats compared to insulin. No adverse events were noted.

Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like